| 1 |
34407567 | Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers. | 2022 Jan |
1 |
| 2 |
35617275 | Acquired chemoresistance drives spatial heterogeneity, chemoprotection and collective migration in pancreatic tumor spheroids. | 2022 |
1 |
| 3 |
33436389 | STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer. | 2021 Jun 1 |
3 |
| 4 |
33753538 | Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation. | 2021 Jun |
3 |
| 5 |
33921102 | Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells. | 2021 Apr 15 |
5 |
| 6 |
34111175 | Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells. | 2021 |
6 |
| 7 |
34353292 | RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin. | 2021 Aug 5 |
2 |
| 8 |
34682775 | RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin. | 2021 Oct 11 |
2 |
| 9 |
31823522 | Identification of chemoresistance-related mRNAs based on gemcitabine-resistant pancreatic cancer cell lines. | 2020 Feb |
2 |
| 10 |
32014934 | Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer. | 2020 Feb |
1 |
| 11 |
32986894 | Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer. | 2020 Dec |
1 |
| 12 |
30999154 | Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. | 2019 Jul |
1 |
| 13 |
31340801 | RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy. | 2019 Jul 24 |
4 |
| 14 |
31652886 | Inhibitory Effect of Oat Bran Ethanol Extract on Survival and Gemcitabine Resistance of Pancreatic Cancer Cells. | 2019 Oct 24 |
1 |
| 15 |
29214667 | Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis. | 2018 Apr |
5 |
| 16 |
29286153 | CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation. | 2018 Mar |
1 |
| 17 |
29803896 | Prognostic value of ribonucleotide reductase subunit M1 (RRM1) in non-small cell lung cancer: A meta-analysis. | 2018 Oct |
1 |
| 18 |
29845287 | Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2‑positive breast cancer. | 2018 Jul |
1 |
| 19 |
30237724 | RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine. | 2018 |
5 |
| 20 |
28196013 | Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy. | 2017 May/Jun |
2 |
| 21 |
28396636 | Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine. | 2017 |
1 |
| 22 |
28422153 | Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma. | 2017 Apr 19 |
1 |
| 23 |
28521448 | Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine. | 2017 May |
1 |
| 24 |
28624910 | Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy? | 2017 Aug |
1 |
| 25 |
28887583 | MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells. | 2017 Oct |
1 |
| 26 |
29152060 | Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine. | 2017 Oct 20 |
1 |
| 27 |
26650486 | The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient. | 2016 Sep |
4 |
| 28 |
26828016 | MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer. | 2016 Apr 1 |
6 |
| 29 |
27335251 | RRM1 *151A>T, RRM1 -756T>C, and RRM1 -585T>Gis associated with increased susceptibility of lung cancer in Chinese patients. | 2016 Aug |
1 |
| 30 |
24792823 | cRGD grafted siRNA nano-constructs for chemosensitization of gemcitabine hydrochloride in lung cancer treatment. | 2015 Mar |
4 |
| 31 |
25187316 | Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones. | 2015 Jan |
1 |
| 32 |
25560468 | Predicting chemosensitivity to gemcitabine and cisplatin based on gene polymorphisms and mRNA expression in non-small-cell lung cancer cells. | 2015 Jan |
2 |
| 33 |
25837929 | Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors. | 2015 Mar |
4 |
| 34 |
25998688 | Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. | 2015 Jul |
1 |
| 35 |
26000095 | Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma. | 2015 Mar |
1 |
| 36 |
26028097 | Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer. | 2015 |
2 |
| 37 |
26092210 | RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients--a short report. | 2015 Aug |
3 |
| 38 |
26137163 | Advanced squamous lung carcinoma in a patient experiencing long-term survival following repeated responses to gemcitabine and cisplatin chemotherapy: A case report. | 2015 Jun |
3 |
| 39 |
26200905 | Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. | 2015 |
3 |
| 40 |
26228206 | The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1). | 2015 Dec 15 |
2 |
| 41 |
26254808 | Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells. | 2015 Nov |
3 |
| 42 |
26323924 | The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer. | 2015 Aug |
3 |
| 43 |
26418006 | Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer. | 2015 |
2 |
| 44 |
26557761 | ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine. | 2015 |
2 |
| 45 |
24018612 | Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines. | 2014 Jan 25 |
1 |
| 46 |
24361227 | Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. | 2014 Mar |
1 |
| 47 |
24588962 | The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitors. | 2014 Apr 1 |
1 |
| 48 |
24591771 | First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients. | 2014 |
1 |
| 49 |
24614341 | Ubiquitination and degradation of ribonucleotide reductase M1 by the polycomb group proteins RNF2 and Bmi1 and cellular response to gemcitabine. | 2014 |
4 |
| 50 |
24647522 | Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression. | 2014 |
5 |